and its receptors may be pharmacological targets for glaucoma management. 3 If true, animal models of glaucoma may be created by disrupting the melatonin system.
The physiological effects of melatonin and its putative endogenous role in IOP regulation may not be solely systemic. In the mammalian eye, melatonin is synthesized rhythmically by retinal photoreceptor cells and the ciliary body, with high levels at night and lower levels during the day, and is secreted into the aqueous humor. 1,2,9,10 Melatonin exerts its action by interacting with a family of G-protein coupled receptors that are negatively coupled with adenylate cyclase. 11 Melatonin receptor subtypes MT 1 and MT 2 reside in the neural retina, the iris, and the ciliary body. 12, 13 and these subtypes are directly implicated in IOP regulation. 7 In addition, a recent study using mice lacking the melatonin receptor type 1 (MT In conclusion, the data indicate that two key characteristics of high-tension primary openangle glaucoma (i.e., loss of retinal ganglion cells and elevated IOP) are present in mice deficient in the MT 1 receptor. We showed that increase in IOP preceded loss of RGCs and that a 4-6 mmHg nocturnal increase in IOP over a long period of time may induce a significant loss (20-30%) of retinal ganglion cells. These studies suggest that dysfunctional melatonin signaling and an associated increase in nocturnal IOP should be considered possible risk factors in the pathogenesis of glaucoma. Increased levels of melatonin during the night (black line) activate MT 1 receptors (black triangles) located in the ciliary body (CB) to reduce aqueous humor production and consequently intraocular pressure. Further investigation is needed on neuroprotective role of melatonin via MT 1 receptors against glaucomatous damage.
